Almirall Celebrates 80 Years, Projects Growth with New Dermatology Drug
Founded 80 years ago in Barcelona, the family-owned Almirall pharmaceutical company, specializing in dermatology, anticipates significant growth with its new drug, Ebglyss, projecting €450 million in sales, while its Ilumetri drug shows 25% yearly growth.
Almirall Celebrates 80 Years, Projects Growth with New Dermatology Drug
Founded 80 years ago in Barcelona, the family-owned Almirall pharmaceutical company, specializing in dermatology, anticipates significant growth with its new drug, Ebglyss, projecting €450 million in sales, while its Ilumetri drug shows 25% yearly growth.
Progress
56% Bias Score
Egypt Partially Pays $120M in Pharmaceutical Arrears, Addressing Drug Shortages
The Egyptian government disbursed 4 billion Egyptian pounds ($80.2 million) to pharmaceutical companies, addressing 6 billion pounds ($120.5 million) in arrears, alleviating drug shortages caused by currency devaluation and import cost increases; additional payments totaling 6 billion pounds ($120.3...
Egypt Partially Pays $120M in Pharmaceutical Arrears, Addressing Drug Shortages
The Egyptian government disbursed 4 billion Egyptian pounds ($80.2 million) to pharmaceutical companies, addressing 6 billion pounds ($120.5 million) in arrears, alleviating drug shortages caused by currency devaluation and import cost increases; additional payments totaling 6 billion pounds ($120.3...
Progress
32% Bias Score
Astellas to Launch Innovative Cancer Treatments in China Amidst Growing Market
Astellas, a multinational pharmaceutical company, is bringing two innovative cancer treatments to China, capitalizing on the country's massive consumer base, strengthened IP protection, and improved innovation climate; China's elderly population exceeded 20% in 2022.
Astellas to Launch Innovative Cancer Treatments in China Amidst Growing Market
Astellas, a multinational pharmaceutical company, is bringing two innovative cancer treatments to China, capitalizing on the country's massive consumer base, strengthened IP protection, and improved innovation climate; China's elderly population exceeded 20% in 2022.
Progress
36% Bias Score
Wegovy Launches in China
The weight-loss drug Wegovy launches in China, offering a potentially effective treatment for the country's large obese population, but also raising questions about affordability and healthcare systems.
Wegovy Launches in China
The weight-loss drug Wegovy launches in China, offering a potentially effective treatment for the country's large obese population, but also raising questions about affordability and healthcare systems.
Progress
40% Bias Score
France's Most Prescribed Drugs
Analysis of the most prescribed drugs in France, highlighting Doliprane's dominance and the high cost of innovative treatments.
France's Most Prescribed Drugs
Analysis of the most prescribed drugs in France, highlighting Doliprane's dominance and the high cost of innovative treatments.
Progress
0% Bias Score
MariTide Trial Results and Market Reaction
Amgen's weight loss drug, MariTide, shows bone density loss in early trials, causing market uncertainty.
MariTide Trial Results and Market Reaction
Amgen's weight loss drug, MariTide, shows bone density loss in early trials, causing market uncertainty.
Progress
0% Bias Score
VersaBank Stock Soars on U.S. Expansion
VersaBank's stock price has more than doubled in the past year, reaching near all-time highs, driven by its US$14-million acquisition of Stearns Bank and expansion into the U.S. market with its receivables purchase program, despite lower-than-expected Q4 earnings due to deal costs.
VersaBank Stock Soars on U.S. Expansion
VersaBank's stock price has more than doubled in the past year, reaching near all-time highs, driven by its US$14-million acquisition of Stearns Bank and expansion into the U.S. market with its receivables purchase program, despite lower-than-expected Q4 earnings due to deal costs.
Progress
24% Bias Score
Pfizer Stock Plunges 50% Amidst Falling Sales and Vaccine Concerns
Pfizer stock is down 50% since early 2022 to $26, driven by a 42% fall in 2023 sales to $58.5 billion following the Covid-19 pandemic and concerns over new leadership's stance on vaccines, despite efforts to cut costs and develop new drugs.
Pfizer Stock Plunges 50% Amidst Falling Sales and Vaccine Concerns
Pfizer stock is down 50% since early 2022 to $26, driven by a 42% fall in 2023 sales to $58.5 billion following the Covid-19 pandemic and concerns over new leadership's stance on vaccines, despite efforts to cut costs and develop new drugs.
Progress
40% Bias Score
France's Healthcare Cost-Cutting Measures Face Backlash
The French government's new measures to curb healthcare spending, including reducing reimbursements for consultations and medications, spark criticism from various stakeholders who express concerns over the potential impact on healthcare access and affordability.
France's Healthcare Cost-Cutting Measures Face Backlash
The French government's new measures to curb healthcare spending, including reducing reimbursements for consultations and medications, spark criticism from various stakeholders who express concerns over the potential impact on healthcare access and affordability.
Progress
40% Bias Score
Algeria Boosts Pharmaceutical Sector with Customs Support
A regional information day in Constantine highlights the importance of accurate customs information for pharmaceutical production and export in Algeria, showcasing government support measures and the perspectives of economic operators.
Algeria Boosts Pharmaceutical Sector with Customs Support
A regional information day in Constantine highlights the importance of accurate customs information for pharmaceutical production and export in Algeria, showcasing government support measures and the perspectives of economic operators.
Progress
24% Bias Score
ELPEN Expands into Middle East Market
Greek pharmaceutical company ELPEN expands into the Middle East by establishing a subsidiary in Dubai, driven by market growth and a strategic focus on direct market access.
ELPEN Expands into Middle East Market
Greek pharmaceutical company ELPEN expands into the Middle East by establishing a subsidiary in Dubai, driven by market growth and a strategic focus on direct market access.
Progress
0% Bias Score
Alzheimer's Research: Advancements and Challenges
This article discusses the latest advancements and challenges in Alzheimer's drug development, focusing on various therapeutic targets, drug repurposing, and the regulatory landscape.
Alzheimer's Research: Advancements and Challenges
This article discusses the latest advancements and challenges in Alzheimer's drug development, focusing on various therapeutic targets, drug repurposing, and the regulatory landscape.
Progress
0% Bias Score